FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Variants of monoclonal antibodies and fragments thereof that bind to the influenza A virus and neutralize the infection caused by the H3 treasure and at least several variants of the influenza A H7 clade are provided. Pharmaceutical composition comprising such antibodies or fragments thereof and the use of an antibody or its fragment in the method of treatment or prevention of influenza infection.
EFFECT: these antibodies and fragments thereof are suitable for controlling the epidemic and pandemic influenza, as well as for providing preventive or therapeutic protection against seasonal influenza.
9 cl, 6 dwg, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA | 2011 |
|
RU2635999C2 |
| ANTIBODIES SUITABLE FOR PASSIVE IMMUNIZATION AGAINST INFLUENZA, AND COMPOSITIONS THEREOF, COMBINATIONS AND METHODS OF USING | 2015 |
|
RU2720282C1 |
| HIGH-AFFINITY HUMAN ANTIBODIES TO CYTOMEGALOVIRUS (CMV) gB PROTEIN | 2011 |
|
RU2613421C2 |
| NEUTRALIZING BINDING MOLECULES DIRECTED AGAINST INFLUENZA VIRUS, AND METHODS OF THEIR APPLICATION | 2016 |
|
RU2721706C2 |
| STRUCTURES AIMED AT AFP/MHC PEPTIDE COMPLEXES AND TYPES OF THEIR USE | 2016 |
|
RU2754041C2 |
| CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
| BIVALENT BISPECIFIC ANTIBODIES | 2008 |
|
RU2547615C2 |
| HUMAN NECTIN-2 SPECIFIC ANTIBODIES | 2020 |
|
RU2820275C2 |
| BIVALENT BISPECIFIC ANTIBODIES | 2008 |
|
RU2575066C2 |
| ANTIBODIES SPECIFIC TO HUMAN NECTIN-4 | 2019 |
|
RU2825839C2 |
